TABLE 1.
Baseline clinical characteristics of participant insulin dysregulated horses.
| Variable | Placebo | Canagliflozin | P‐value |
|---|---|---|---|
| (n = 8) | (n = 8) | ||
| Age (years) | 16.0 ± 4.8 | 11.1 ± 5.6 | .08 |
| Sex (mare/gelding) | 4/4 | 5/3 | .6 |
| Weight (kg) | 282 ± 95 | 353 ± 146 | .3 |
| BCS | 6.75 (1.875) | 7.5 (1.375) | .5 |
| CNS | 3.5 (1.375) | 4 (1.25) | .8 |
| Fasting plasma insulin (μIU/mL) | 18.8 ± 12.3 | 32.1 ± 14.6 | .07 |
| Fasting plasma glucose (mmol/L) | 5.1 ± 0.4 | 5.2 ± 0.4 | .7 |
| Previous laminitis (yes/no) | 7/1 | 8/0 | .3 |
Note: Values are mean ± SD, median (interquartile range), or n/n (count number).
Abbreviations: BCS, body condition score; CNS, cresty neck score.